Lenar Aimee J. sold $259K of BHC

Lenar Aimee J. (President, US Pharma) sold 36,827 shares of Bausch Health Companies Inc. (BHC) at $7.03 ($0.26M total) on 2026-08-19 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lenar Aimee J.
Published Aug 20, 2026, 8:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 8:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BHC
Bearish
medium confidence
Mentioned
$BHC
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BHCBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment for BHC.

02

Market read

A senior executive's stock sale adds a modest data point for traders monitoring BHC.

03

What to watch

The insider retains a large stake (334,853 shares) indicating continued confidence.

Relevance 3/10Novelty 5/10Timing: post‑market filing on Aug 20

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$BHCBearishMedium confidence
Context

President of US Pharma sold 36,827 shares for $258,894 via a 10b5‑1 plan.

Expected impact

Potential modest downward pressure on BHC stock.

Evidence & confidence

Sale size is modest relative to holdings but involves a senior executive; market may interpret as a slight bearish signal.

Market effects

Limited impact on the broader pharma sector.

No significant regional effect.

Minimal global relevance.

Counterpoint

The sale could be routine portfolio rebalancing, not a bearish sign.

Key entities

  • Lenar Aimee J.

    President, US Pharma at Bausch Health Companies.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BHCMedAI 8/10

Bausch Health Soars 21% on Beat-and-Raise Quarter: Core EBITDA Hits a “First Time” Milestone

Bausch Health (BHC) rose 21% after reporting adjusted EPS of $1.77, beating estimates, and raising its full-year outlook. Core EBITDA, excluding Bausch + Lomb, exceeded $1 billion for the first time. Xifaxan's growth and debt reduction contributed to the results. The company also anticipates a Medicare price impact on Xifaxan in 2027. AbbVie (ABBV) and Teva (TEVA) face similar challenges with their drugs. BHC's forward P/E remains below its five-year average.

$BHCHighAI 8/10

Bausch Health Companies Inc (BHC) Q3 2026 Earnings Call Highlights: Adjusted EBITDA Tops

Bausch Health (BHC) reported Q3 2026 earnings, raising full-year guidance. Adjusted EBITDA exceeded $1B. CFO JJ Sharon noted a $100M+ impact from Xifaxan price adjustments. CEO Thomas Appio discussed Solta's growth and regulatory timelines. Salix revenue rose 16% to $831M, driven by Xifaxan. The company reduced debt by $521M and announced a $50M share repurchase program.